BG100™ is a highly efficient and partially purified molluscan beta-glucuronidase (bgluc) derived from ocean-fresh Red abalone Haliotis rufescens entrails. This hyperthermophilic bgluc catalyzes faster hydrolysis reactions. It demonstrates a wider substrate-adaptability and greater efficiency than Helix pomatia, Patella vulgata or even generic abalone-sourced bgluc. All clinical and forensic glucuronidated analytes are deconjugated in a one-run incubation. Complete recoveries are achieved in less than 90 minutes on both high and low concentrations of analytes.
– Deconjugate glucuronides (and sulfate esters in low proportions) by catalyzing hydrolysis.
– Screening and quantification of metabolized molecules in body fluids (urine, blood, plasma, meconium, bile)
BG100™ is superior to other molluscan beta-glucuronidase preparations by its ability to provide a comprehensive and complete hydrolysis in 18 to 90 minutes. It consistently hydrolyzes all opioids-opiates glucuronides including codeine-6-glucuronide (C6G) with over 87% recovery and has been validated in SAMHSA-certified drug-testing laboratories (Technical Note available on request). Herbal cannabinoids (THCCOOH, THC, CBD,…) and benzodiazepines are recovered in the same incubation. BG100™ has also been validated with a series of emerging designer drugs such as synthetic cannabinoids (spice, K2,…) and synthetic cathinones (MDPV etc). In 2013 the US-National Institute on Drug-Abuse (NIDA) observed that metabolites of synthetic cannabinoids can be hydrolyzed with 10-fold less bgluc than with generic abalone preparations. As a result a high-throughput screening method was made possible.
BG100™ is LC-column compatible and enables high-throughput methods. Matrix effect or even column-clogging are common issues particularly with LC-MS/MS or HPLC users. BG100™ goes through an advanced purification process relying on ocean-fresh (never freeze-dried) Red abalone entrails. The resultant enzyme preparation BG100™ is optimized to minimize matrix effects, improve data quality, and achieve short injection-to-injection cycles. In high-throughput drug-testing BG100™ contributes to no or reduced sample preparation such as dilute-and-shoot or protein precipitation. In any case, quality of readings is increased through less background-noise interferences. Improved LOQ and LOD bring further accuracy in TDM (e.g. low-benzodiazepines), workplace drug-testing and forensic (e.g. designer drugs) as well as anti-doping and clinical steroid-profiling.
In particular BG100™ replaces Helix pomatia (G7017 type HP-2) beta-glucuronidase, is autosampler-friendly, provides a two to ten-fold higher hydrolysis velocity and increases reading quality. Former overnight hydrolysis incubations are performed in less than 90 minutes, eliminating the risk of conversions and analyte instability.
– Reduce incubation time down to 3-90 minutes with recovery rates >90%.
– Simplify laboratory workflow with one sample preparation: one hydrolysis – one analysis .
– Guarantee highest recovery rates at both high and low substrate concentrations.
– Enable high-throughput liquid chromatography method.
– Decrease matrix effect.
– Increase quality of readings.
– Extend column lifetime and chromatography instruments up-time.
– Optimized hydrolysis protocols (Technical Notes) and technical support available.
|β-Glucuronidase activity||> 100,000 U/ml (Phenolphthalein-β-D-glucuronide as substrate)|
|Sulfatase activity||< 8,000 U/ml|
|Form||Liquid amber solution, autosampler friendly|
|Storage temperature||+2 – +8 °C|
|β-Glucuronidase activity||1,000,000 – 3,200,000 U/g (Phenolphthalein-β-D-glucuronide as substrate)|
|Sulfatase activity||< 150,000 U/g|
|Form||light brown lyophilized powder|
|Storage temperature||-20 °C|